Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 208

Rapt adapts IPO stance

The Celgene and GV-backed cancer and atopic dermatitis drug developer is now targeting $75m in an initial public offering it postponed in August.

Oct 24, 2019

Mastercard sends for SessionM in acquisition deal

Salesforce Ventures is set to exit customer engagement platform developer SessionM, which has agreed to a purchase by Mastercard.

Oct 24, 2019

SoftBank sorts We Company with $9.5bn financing package

Jin Jiang International and Legend Holdings will get exit routes through the deal, which is set to give SoftBank a stake in the workspace provider sized at about 80%.

Oct 23, 2019

PropertyGuru moves away from IPO

Emtek, which had planned to sell as much as $55m worth of shares, will have to wait longer for an exit after the real estate marketplace withdrew from the proposed offering.

Oct 23, 2019

Roku attacks $150m Dataxu acquisition

Sky will exit through the deal without much of a return, having reportedly invested in video ad buying platform Dataxu at a $1bn valuation.

Oct 23, 2019

MediaLab rescues Kik Messenger

MediaLab has bought Kik Messenger from Tencent-backed Kik Interactive, saving the app from closure amid the latter's legal issues surrounding its crypto token.

Oct 22, 2019

Xandr commissions Duke-backed Clypd

AT&T advertising unit Xandr has bought Clypd, a TV advertising optimisation service that counts Duke University as a shareholder.

Oct 21, 2019

Clypd attaches itself to AT&T

Tivo and RTL exited television advertising data platform Clypd in an acquisition by AT&T's advertising services subsidiary, Xandr.

Oct 21, 2019

TV Time clocks up MediaMorph acquisition

Liberty Global Ventures and Motorola Mobility Ventures both scored exits from the media content monetisation service in an acquisition by TV Time.

Oct 21, 2019

Phathom measures out IPO terms

Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.

Oct 17, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here